Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 1/2014

Open Access 01-03-2014 | Prevention and Early Detection (N Arber, Section Editor)

Lifestyle Modifications and Colorectal Cancer

Authors: Lukasz Durko, Ewa Malecka-Panas

Published in: Current Colorectal Cancer Reports | Issue 1/2014

Login to get access

Abstract

Many studies suggest that Western lifestyle and dietary factors may be responsible for the high incidence of colorectal cancer in industrialized countries. Consumption of high amounts of red and processed meat and low intake of fiber and multiple protective phytochemicals found in fruits, vegetables, and whole grains might be responsible for the high incidence of this neoplasm in the Western world. Additionally, obesity, lack of physical activity, tobacco and alcohol use, sleep deprivation, and other factors have been proven to further increase the risk of colorectal cancer. Identifying and understanding the mechanisms through which they impact colon carcinogenesis is needed for the introduction of protective lifestyle recommendations.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2010;24:417–25.PubMedCrossRef
3.
Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009;125:171–80.PubMedCrossRef
4.
Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688–94.PubMedCrossRef
5.
6.
Slomka M, Kaczka A, Malecka-Panas E. Environmental factors and the risk of colorectal adenomas and cancer. Clin Exp Med Lett. 2008;49(2):77–81.
7.
8.
9.
Scharlau D, Borowicki A, Habermann N, et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res. 2009;682:39–53.PubMedCrossRef
10.
Vergara-Castaneda HA, Guevara-Gonzalez RG, Ramos-Gomez M, Reynoso-Camacho R, Guzman-Maldonado H, Feregrino-Perez AA, et al. Non-digestible fraction of cooked bean (Phaseolus vulgaris L.) cultivar Bayo Madero suppresses colonic aberrant crypt foci in azoxymethane-induced rats. Food Funct. 2010;1:294–300.PubMedCrossRef
11.
Reddy BS, Hirose Y, Cohen LA, Simi B, Cooma I, Rao CV. Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention. Cancer Res. 2000;60:4792–7.PubMed
12.
Kaczmarczyk MM, Miller MJ, Freund GG. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metab Clin Exp. 2012;61:1058–66.PubMedCentralPubMedCrossRef
13.
Feregrino-Perez AA, Berumen LC, Garcia-Alcocer G, Guevara-Gonzalez RG, Ramos-Gomez M, Reynoso-Camacho R, et al. Composition and chemopreventive effect of polysaccharides from common beans (Phaseolus vulgaris L.) on azoxymethane-induced colon cancer. J Agric Food Chem. 2008;56:8737–44.PubMedCrossRef
14.
Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst. 1992;84:1887–96.PubMedCrossRef
15.
Willett WC, Stampfer MJ, Colditz GA, et al. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323:1664–72.PubMedCrossRef
16.
Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340:169–76.PubMedCrossRef
17.
18.
Krebs-Smith SM, Kantor LS. Choose a variety of fruits and vegetables daily: understanding the complexities. J Nutr. 2001;131:487S–501S.PubMed
19.
Johnston CS, Taylor CA, Hampl JS. More Americans are eating “5 a day” but intakes of dark green and cruciferous vegetables remain low. J Nutr. 2000;130:3063–7.PubMed
20.
Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet. 2003;361:1496–501.PubMedCrossRef
21.
van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, et al. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2009;89:1441–52.PubMedCrossRef
22.
Powers HJ. Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr. 2005;135:2960S–6S.PubMed
23.
Wang TP, Hsu SH, Feng HC, Huang RF. Folate deprivation enhances invasiveness of human colon cancer cells mediated by activation of sonic hedgehog signaling through promoter hypomethylation and cross action with transcription nuclear factor-kappa B pathway. Carcinogenesis. 2012;33(6):1158–68.PubMedCrossRef
24.
Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132:2350S–5S.PubMed
25.
Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–9.PubMedCrossRef
26.
27.
Majumdar AP, Kodali U, Jaszewski R. Chemopreventive role of folic acid in colorectal cancer. Front Biosci. 2004;9:2725–32.PubMedCrossRef
28.
Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer. A meta-analysis of prospective studies. JAMA. 2010;303:1077–83.PubMedCrossRef
29.
30.••
Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS ONE. 2011;6:e20456. The article is a meta-analysis of 24 prospective cohort studies conducted in the USA, in ten European countries as part of EPIC, and in Finland, Sweden, the Netherlands, Japan, Australia, China, and Singapore. The data presented provide very strong evidence that “the risk increase in colorectal cancer estimated in linear dose-response models was 14% for every 100 g/day increase of total red and processed meats, 25% in colon cancer, and 31% in rectal cancer.” The authors suggest that limiting red meat consumption could be a primary preventive measure in CRC..PubMedCentralPubMedCrossRef
31.
Ishikawa S, Tamaki S, Ohata M, Arihara K, Itoh M. Heme induces DNA damage and hyperproliferation of colonic epithelial cells via hydrogen peroxide produced by heme oxygenase: a possible mechanism of heme-induced colon cancer. Mol Nutr Food Res. 2010;54:1182–91.PubMed
32.
Knobel Y, Weise A, Glei M, Sendt W, Claussen U, Pool-Zobel BL. Ferric iron is genotoxic in non-transformed and pre-neoplastic human colon cells. Food Chem Toxicol. 2007;45:804–11.PubMedCrossRef
33.
O’Callaghan NJ, Toden S, Bird AR, Topping DL, Fenech M, Conlon MA. Colonocyte telomere shortening is greater with dietary red meat than white meat and is attenuated by resistant starch. Clin Nutr. 2012;31:60–4.PubMedCrossRef
34.
Biasi F, Mascia C, Poli G. The contribution of animal fat oxidation products to colon carcinogenesis, through modulation of TGF-β1 signaling. Carcinogenesis. 2008;29:890–4.PubMedCrossRef
35.
Sugimura T, Wakabayashi K, Nakagama H, Nagao M. Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci. 2004;95:290–9.PubMedCrossRef
36.
Martinez ME, Jacobs ET, Ashbeck EL, et al. Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis. 2007;28:2019–27.PubMedCrossRef
37.
Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res. 2010;27:2085–97.PubMedCentralPubMedCrossRef
38.
Derry M, Raina K, Agarwal R, Agarwal C. Differential effects of grape seed extract against human colorectal cancer cell lines: the intricate role of death receptors and mitochondria. Cancer Lett. 2013;334:69–78.CrossRef
39.
40.
Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia. 2010;12:415–24.PubMedCentralPubMed
41.
Kauntz H, Bousserouel S, Gosse F, Raul F. The flavonolignin silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis. 2012;17:797–809.PubMedCrossRef
42.
Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog. 2013;52:195–206.PubMedCentralPubMedCrossRef
43.
Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamics consequences. Clin Cancer Res. 2006;12:2944–50.PubMedCrossRef
44.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631–52.PubMedCrossRef
45.•
Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm. 2010;343(9):489–99. Curcumin is a phenolic extract of the spice turmeric (Curcuma longa) with chemopreventive potential. The article presents recent data regarding the molecular background on the interaction curcumin with numerous signaling pathways. Additionally, the authors describe promising results of early-phase clinical trials of this substance in the treatment of neoplasms (multiple myeloma, pancreatic cancer, and colon cancer)..CrossRef
46.
Ye SF, Hou ZQ, Zhong LM, Zhang QQ. Effect of curcumin on the induction of glutathione S-transferases and NADP(H):quinone oxidoreductase and its possible mechanism of action. Yao Xue Xue Bao. 2007;42:376–80.PubMed
47.
Yogosawa S, Yamada Y, Yasuda S, Sun Q, Takizawa K, Sakai T. Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. J Nat Prod. 2012;75:2088–93.PubMedCrossRef
48.
Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V, et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 2007;7:333–42.PubMedCrossRef
49.
Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila). 2012;5:205–15.CrossRef
50.
Chen C, Liu Y, Chen Y, Xu J. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors. Cancer Biol Ther. 2011;12:797–807.PubMedCrossRef
51.
Giladi N, Kazanov D, Shpitz B, Aroch I, Kraus S, Arber N. Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin Investig Drugs. 2010;19 Suppl 1:S117–24.PubMedCrossRef
52.
Aroch I, Kraus S, Naumov I, et al. Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats. Ther Adv Gastroenterol. 2010;3(5):281–9.CrossRef
53.
Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9:429–39.PubMedCentralPubMedCrossRef
54.
Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar AP, et al. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One. 2013. doi:10.​1371/​journal.​pone.​0068543.
55.
Patel BB, Gupta D, Elliot AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res. 2010;30(2):319–25.PubMedCentralPubMed
56.
57.
Larsen CA, Dashwood RH. (-)-Epigallocatechin-3-gallate inhibits Met-signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys. 2010;501:52–7.PubMedCentralPubMedCrossRef
58.
Thakur VS, Ruhul Amin AR, Paul RK, Gupta K, Hastak K, Agarwal MK, et al. p53-dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Lett. 2010;296:225–32.PubMedCentralPubMedCrossRef
59.
Trudel D, Labbe DP, Araya-Farias M, et al. A two stage singe arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013;13(2):357–61.CrossRef
60.•
Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254–8. The authors present a very detailed molecular analysis of the role of microbial colonic flora in the development of adenomas. The results indicate the importance of IL-17 and IL-23 signaling and mucosal barrier integrity in colon adenoma and cancer growth..PubMedCentralPubMed
61.
Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–8.PubMedCentralPubMedCrossRef
62.
Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120–3.PubMedCentralPubMedCrossRef
63.
64.
Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O’Brien M, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem. 2006;281:24449–54.PubMedCrossRef
65.
Matsumoto M, Kurihara S, Kibe R, Ashida H, Benno Y. Longevity in mice is promoted by probiotic-induced suppression of colonic senescence dependent on up regulation of gut bacterial polyamine production. PLoS ONE. 2011;6:e23652.PubMedCentralPubMedCrossRef
66.
Park E, Jeon GI, Park JS, Paik HD. A probiotic strain of Bacillus polyfermenticus reduces DMH induced precancerous lesions in F344 male rat. Biol Pharm Bull. 2007;30:569–74.PubMedCrossRef
67.
Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140:603–13.PubMedCrossRef
68.•
Haas SL, Ye W, Lohr JM. Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care. 2012;15:457–67. This review summarizes recent evidence on the impact of alcohol consumption on the risk of gastrointestinal neoplasms. It presents current knowledge of the molecular bases of ethanol-induced carcinogenesis, mostly through oxidative stress mechanisms and DNA damage caused by the ethanol metabolite acetaldehyde. The authors also present the results of recent systematic reviews which indicate that alcohol intake is strongly related to increased risk of gastrointestinal cancers (including colon cancer)..PubMedCrossRef
69.
Blasiak J, Trzeciak A, Malecka-Panas E, Drzewoski J, Wojewodzka M. In vitro genotoxicity of ethanol and acetaldehyde in human lymphocytes and the gastrointestinal tract mucosa cells. Toxicol In Vitro. 2000;14:287–95.PubMedCrossRef
70.
Jacobson JS, Neugut AI, Murray T, Garbowski GC, Forde KA, Treat MR, et al. Cigarette smoking and other behavioral risk factors for recurrence of colorectal adenomatous polyps (New York City, NY, USA). Cancer Causes Control. 1994;5:215–20.PubMedCrossRef
71.
Leufkens AM, Van Duijnhoven FJ, Siersema PD, et al. Cigarette smoking and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study. Clin Gastroenterol Hepatol. 2011;9(2):137–44.PubMedCrossRef
72.
Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. The modulating role of nuclear factor-κB in the action of α7-nicotinicacetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther. 2004;311:123–30.PubMedCrossRef
73.
Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH. Nicotine promotes colon tumor growth and angiogenesis through β-adrenergic activation. Toxicol Sci. 2007;97:279–87.PubMedCrossRef
74.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRef
75.••
Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11:19–30. The publication is a meta-analysis of 56 studies, including 93,812 cases. The authors indicate that “BMI < 23.0 kg/m 2 , BMI of 23.0-24.9, 25.0-27.4, 27.5-29.9 and > or = 30.0 kg/m 2 were associated with 14%, 19%, 24% and 41% increased risks of colorectal cancer, respectively.” Additionally “the association was stronger for colon than rectal cancer, for men than women,” These valuable data strongly emphasize the impact of obesity on CRC risk..PubMedCrossRef
76.
Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–47.PubMedCrossRef
77.••
Nam SY, Kim BC, Han KS, et al. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol. 2010;8:443–50. The authors evaluated the associations between waist circumference, visceral adipose tissue volume, and colorectal adenoma type and prevalence in 3,922 participants who underwent colonoscopy and computer tomography. The analysis provided strong evidence that “the risk of colorectal adenomas increased with increasing visceral adipose tissue volume in both sexes. Waist circumference was associated with colorectal adenomas in men, but not in women. High volume of visceral adipose tissue (>or=1000 cm 3 ) had a positive association with larger adenomas (>or=10 mm) and multiple adenomas.” The results presented indicate that abdominal visceral adipose tissue volume is a better predictor of colorectal adenomas than BMI or waist circumference in men and women..PubMedCrossRef
78.
Gutierez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diabetes Rep. 2009;9(1):26–32.CrossRef
79.
Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta. 1801;2010:252–65.
80.
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.PubMedCrossRef
81.
Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24:275–81.PubMedCrossRef
82.
Booth FW, Chakravarthy MV, Gordon SE, Spangenburg EE. Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. J Appl Physiol. 2002;93:3–30.PubMed
83.
84.••
Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer. 2011;104(5):882–5. This is a meta-analysis of 20 studies evaluating the association between physical activity and the prevalence of colon adenomas. The authors showed that “a significant inverse association between physical activity and colon adenomas was found with an overall RR of 0.84 (CI: 0.77-0.92). The association was similar in men (RR=0.81, CI: 0.67-0.98) and women (RR=0.87, CI: 0.74-1.02). The association appeared slightly stronger in large/advanced polyps (RR=0.70, CI: 0.56-0.88).” The study strongly emphasizes the important role of physical activity in CRC prevention..PubMedCentralPubMedCrossRef
85.
86.
Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67:253–6.PubMedCrossRef
87.
Asghar M, George L, Lokhandwala MF. Exercise decreases oxidative stress and inflammation restores renal dopamine D1 receptor function in old rats. Am J Physiol Renal Physiol. 2007;293:F914–9.PubMedCrossRef
88.
Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105:956–64.PubMedCrossRef
89.
90.
Kim SY, Jun TW, Lee YS, Na HK, Surh YJ, Song W. Effects of exercise on cyclooxygenase-2 expression and nuclear factor-κB DNA binding in human peripheral blood mononuclear cells. Ann N Y Acad Sci. 2009;1171:464–71.PubMedCrossRef
91.
Poulsen HE, Weimann A, Loft S. Methods to detect DNA damage by free radicals: relation to exercise. Proc Nutr Soc. 1999;58:1007–14.PubMedCrossRef
92.
93.
Hrushesky WJ, Lannin D, Haus E. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation. J Natl Cancer Inst. 1998;90:1480–4.PubMedCrossRef
94.
Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255–9.PubMedCrossRef
95.
Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006;15:R271–7.PubMedCrossRef
96.
Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008;6:1786–93.PubMedCrossRef
97.
Wozniak K, Arabski M, Malecka-Panas E, Drzewoski J, Blasiak J. DNA damage in human colonic mucosa cells induced by bleomycin and the protective action of vitamin E. Cell Mol Biol Lett. 2003;9:31–45.
98.
Blasiak J, Arabski M, Pertynski T, Malecka-Panas E, et al. DNA damage in human colonic mucosa cells evoked by nickel and protective action of quecetin – involvement of free radicals? Cell Biol Toxicol. 2002;18:279–88.PubMedCrossRef
99.
Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet. 2007;369:1603–13.PubMedCrossRef
100.
Metadata
Title
Lifestyle Modifications and Colorectal Cancer
Authors
Lukasz Durko
Ewa Malecka-Panas
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 1/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0203-4

Other articles of this Issue 1/2014

Current Colorectal Cancer Reports 1/2014 Go to the issue

Prevention and Early Detection (N Arber, Section Editor)

Curcumin Alone and in Combination for Prevention of Colorectal Cancer

Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Fecal Biomarkers for Research on Dietary and Lifestyle Risk Factors in Colorectal Cancer Etiology

Prevention and Early Detection (N Arber, Section Editor)

Should Microsatellite Instability Be Tested in All Cases of Colorectal Cancer?

Personalized Medicine in Colorectal Cancer (CMS Rocha-Lima, Section Editor)

Prevention of Colorectal Cancer: The Future Is Now

Prevention and Early Detection (N Arber, Section Editor)

Fibroblast Growth Factor Receptor-2 IIIc as a Novel Molecular Target in Colorectal Cancer

Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Environmental Exposure and Tumor Heterogeneity in Colorectal Cancer Risk and Outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits